After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the blame on alleged ...
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Hosted on MSN27d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its useThe Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's ...
Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Novo Nordisk (NVO) said its popular diabetes ... and death from cardiovascular disease in adults with type 2 diabetes and chronic kidney disease. The Danish drugmaker said the approval makes ...
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results